<DOC>
	<DOCNO>NCT02251483</DOCNO>
	<brief_summary>The primary objective study determine whether give SBI medical food start maintenance health management chronic loose frequent stool IBS-D subject SIBO successful treatment rifaximin lead prolong duration benefit delay symptom recurrence . SBI main ingredient EnteraGam™ , orally administer prescription medical food dietary management patient enteropathy chronic loose frequent stool , include patient IBS-D .</brief_summary>
	<brief_title>Use SBI IBS Subjects Following Successful Treatment Small Intestinal Bacterial Overgrowth</brief_title>
	<detailed_description>Irritable bowel syndrome ( IBS ) one common gastrointestinal disorder , global prevalence 11 % . IBS manifest 3 major form ; diarrhea-predominant ( IBS-D ) , constipation-predominant ( IBS-C ) , mixed ( IBS-M ) , predominantly characterize symptom abdominal pain , change stool frequency consistency , abdominal bloating . SIBO condition increase number bacteria small bowel , typically include overgrowth coliform bacteria normally find colon . These ferment carbohydrate gas ( measure use lactulose breath test ( LBT ) ) , SIBO hypothesis propose expansion bacteria small bowel lead IBS symptom include bloating , abdominal discomfort change stool form . The antibiotic rifaximin use treat IBS-D , show normalize LBT 70 % subject . Despite success , symptom SIBO tend recur , usually within 4 month finish antibiotic treatment . Therefore , remain significant need identify therapeutic agent maintain health subject IBS SIBO increase duration benefit subject IBS SIBO follow antibiotic treatment . SBI intend dietary management enteropathy medical supervision patient chronic loose frequent stool , include IBS-D patient . In vitro animal study show SBI support digestive absorptive property intestinal tract : 1 . Binding neutralize microbial component 2 . Helping maintain beneficial gut microbiota 3 . Managing gut barrier function 4 . Maintaining GI immune balance Clinical study also demonstrate oral SBI improve nutrient absorption , nutritional status GI symptoms patient HIV-associated enteropathy , IBS-D , malnutrition . It important note SBI use treat patient IBS-D enteropathy , give medical food assist maintenance health . This study ass whether give SBI medical food subject IBS-D SIBO successfully complete course rifaximin lead prolong maintenance health duration benefit antibiotic treatment IBS-D patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Male female age 1875 year old Meet Rome II criterion IBSD Meet criterion SIBO If ≥50 year old , colonoscopy must complete within past 10 year Have complete course antibiotic treatment rifaximin successfully respond treatment . Had intestinal surgery ( except appendectomy cholecystectomy ) Pelvic floor dysfunction Pregnancy nursing mother History bowel obstruction History celiac disease History inflammatory bowel disease Cirrhosis Diabetes Use tricyclic antidepressant Use antidiarrheal medication Allergy hypersensitivity beef component SBI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>DIBS</keyword>
	<keyword>SIBO</keyword>
</DOC>